Overview

Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis

Status:
Terminated

Trial end date:
2021-08-24

Target enrollment:

Participant gender:

Summary

This is an open label, single-arm, proof of mechanism study to explore the efficacy and safety of rectally administered BBT-401-1S in subjects with ulcerative colitis.

Phase:

Phase 1

Details

Lead Sponsor:

Bridge Biotherapeutics, Inc.

Collaborator:

Covance